(firstQuint)A Single Ascending Dose Study of CD101 IV in Healthy Subjects.

 This is a Phase 1, single-center, prospective, randomized, double-blind study of ascending single doses of CD101 Injection administered IV to healthy adult subjects.

 In this study, subjects in 4 cohorts of 8 subjects, each will be randomized to receive single IV doses of CD101 Injection or placebo.

 Dose levels of CD101 to be assessed will follow an ascending single-dose regimen.

.

 A Single Ascending Dose Study of CD101 IV in Healthy Subjects@highlight

A single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CD101 IV